Clinical trials: Non Small Cell Lung Carcinoma NSCLC, open to volunteers
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 67 sites in United States, China and 2 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Non Small Cell Lung Cancer
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
- Trial name
- CREATE (NCT05059951)
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 15,000 people
- Sponsor
- Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
This is a 2:1 randomized multicentre open label phase III study of radiation combined with standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5 metastases) NSCLC.
- Trial name
- ANDROMEDA (NCT06141070)
- Testing
- Standard systemic therapy + radiotherapy, Standard systemic therapy
- Where
- 6 sites in Sweden
- Volunteers
- 240 people
- Sponsor
- Vastra Gotaland Region
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in…
- Trial name
- UmbREALung (NCT06726720)
- Where
- 70 sites in France, Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Asymptomatic Brain Metastases, Driver Mutation Positive Non-small Cell Lung Cancer
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases.
- Trial name
- NCT05236946
- Testing
- Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor
- Where
- India
- Volunteers
- 190 people
- Sponsor
- Tata Memorial Hospital
Lung Neoplasms, Lymph Node Excision
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules.
- Trial name
- NCT04631770
- Testing
- Systemic mediastinal lymph node dissection, Spared mediastinal lymph node dissection
- Where
- China
- Volunteers
- 1,362 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy…
- Trial name
- NCT06123754
- Testing
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
NSCLC Stage IV Without EGFR/ALK Mutation
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases.
- Trial name
- NCT06947694
- Testing
- chemotherapy + PD-1 inhibitors
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Xinqiao Hospital of Chongqing
Lung Cancer, Pneumonitis
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy.
- Conditions
- Lung Cancer, Pneumonitis, Radiation-Induced Lung Injury, Immunotherapy-Induced Pneumonitis
- Trial name
- INSPIRE-CRT (NCT06688422)
- Testing
- incentive spirometry
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cooper Norcross Health
Oligometastatic Lung Tumor, NSCLC (Non-small Cell Lung Cancer)
Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup
Pulmonary tumors, whether primary or metastatic, represent a major challenge in oncology. Primary lung cancers are responsible for nearly 37,000 deaths per year in France, highlighting the critical importance of their management.
- Conditions
- Oligometastatic Lung Tumor, NSCLC (Non-small Cell Lung Cancer), SBRT
- Trial name
- SPARROW (NCT07441941)
- Where
- 2 sites in France
- Volunteers
- 190 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Lung Cancer, Non-Small Cell
Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC
This real-word study is designed to prospectively explore whether local treatment (surgery, ablation, radiotherapy and others) can prolong the time to treatment discontinuation during 1L lorlatinib treatment in Chinese patients…
- Trial name
- COMLORLA (NCT06690541)
- Testing
- Lorlatinib 100 mg
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-Small Cell Lung Cancer
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping.
- Trial name
- NCT07619339
- Testing
- Tepotinib, Ivonescimab
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer, Minimal Residual Disease
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
This is a multicenter, prospective, observational pilot cohort study in patients with surgically resected non-small cell lung cancer (NSCLC, pathologic stage IA3-IIIA).
- Trial name
- LUNG-MRDetect (NCT07921888)
- Testing
- Patient-specific tumor-informed MRD assay (plasma and bronchial washing ctDNA), Bronchoscopy with bronchial washing for reserach
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Eun Hye Lee
Lung Cancer
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
In recent years, an increasing number of pulmonary nodules have been detected through CT screening. The traditional surgical method for lung cancer is lobectomy combined with lymph node dissection.
- Trial name
- NCT06644066
- Testing
- Partial pressure of Oxygen Control method
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Non-Small Cell Lung Cancer, Chemotherapy
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics…
- Conditions
- Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
- Trial name
- NCT06896422
- Testing
- Glutathione, PD1 Inhibitor, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Non-Small Cell Lung Cancer, ROS1 Gene Rearrangement
Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC
The purpose of this project is to conduct an observational study on the efficacy and safety of entrectinib in real-world patients with ROS1-positive NSCLC who have received entrectinib treatment, while exploring the mechanism of…
- Conditions
- Non-Small Cell Lung Cancer, ROS1 Gene Rearrangement, Resistance, Targeted Therapy
- Trial name
- NCT06694129
- Testing
- Entrectinib
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, China
Non Small Cell Lung Cancer
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as…
- Trial name
- NCT06514027
- Testing
- BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- BeBetter Med Inc
Squamous Non-Small Cell Lung Cancer SqNSCLC
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
The goal of this single-arm, multi-center phase II clinical study is to evaluate the efficacy and safety of recombinant human endostatin (rh-Endostatin) combined with nab-paclitaxel, platinum-based chemotherapy, and PD-1…
- Trial name
- NCT06747169
- Testing
- Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
- Volunteers
- 32 people
- Sponsor
- Jian-Guo Zhou, MD, PhD
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Lung Cancer
DNA Analysis of Blood and Tissue From Patients With Lung Cancer
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00471978
- Where
- 2 sites in United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.